Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sabina Buntich"'
Autor:
Nacera Mellal, Rogely W. Boyce, Kathrin Locher, Steven K. Boyd, Melanie Felx, Jacquelin Jolette, Nancy Doyle, Michael S. Ominsky, Sabina Buntich, Aurore Varela, Susan Y. Smith, Ian Pyrah
Publikováno v:
Journal of Bone and Mineral Research. 32:788-801
Romosozumab (Romo), a humanized sclerostin antibody, is a bone-forming agent under development for treatment of osteoporosis. To examine the effects of Romo on bone quality, mature cynomolgus monkeys (cynos) were treated 4 months post- ovariectomy (O
Autor:
Aurora Varela, Luc Chouinard, Sabina Buntich, Nacera Mellal, Michael S. Ominsky, Peter C. Mann, Jacquelin Jolette, Rana Samadfam, Melanie Felx, Rogely W. Boyce, Kathrin Locher, Susan Y. Smith, Ian Pyrah
Publikováno v:
Regulatory Toxicology and Pharmacology. 81:212-222
Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling. Blockade of sclerostin binding to low-dens
Autor:
Rogely W. Boyce, Sabina Buntich, J. Ignacio Aguirre, Yudong D. He, Efrain Pacheco, Cynthia A. Afshari, Scott Taylor, Ian Pyrah, Michael S. Ominsky, Danielle L. Brown, Paul Nioi, Thomas J. Wronski, Rong Hu
Publikováno v:
Bone. 84:148-159
Inhibition of sclerostin with sclerostin antibody (Scl-Ab) has been shown to stimulate bone formation, decrease bone resorption, and increase bone mass in both animals and humans. To obtain insight into the temporal cellular and transcriptional chang
Autor:
Sabina Buntich, Amber Umble-Romero, Wei-Jian Pan, L Som, Jason M. Gow, C D Krill, Yu Sun, Samantha P. Prokop, Kathleen Köck, Alexander Colbert, Yu Zhang, Wayne Tsuji, Jennifer E. Towne, T J Goletz, M W Trimble, William A. Rees, John P. Gibbs, Michelle Horner, J C O'Neill, Kathryn J. Newhall
Publikováno v:
British Journal of Pharmacology. 172:159-172
Background and Purpose AMG 139 is a human anti-IL-23 antibody currently in a phase II trial for treating Crohn's disease. To support its clinical development in humans, in vitro assays and in vivo studies were conducted in cynomolgus monkeys to deter
Autor:
Michael S, Ominsky, Steven K, Boyd, Aurore, Varela, Jacquelin, Jolette, Melanie, Felx, Nancy, Doyle, Nacera, Mellal, Susan Y, Smith, Kathrin, Locher, Sabina, Buntich, Ian, Pyrah, Rogely W, Boyce
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 32(4)
Romosozumab (Romo), a humanized sclerostin antibody, is a bone-forming agent under development for treatment of osteoporosis. To examine the effects of Romo on bone quality, mature cynomolgus monkeys (cynos) were treated 4 months post- ovariectomy (O
Autor:
Sabina Buntich, Robert Ortiz, Babette M. Boren, Michelle Horner, Tsui C. Cheah, Suzanne T. Wolford, Wayne Tsuji, Eric A. Butz, Larry C. Wienkers, Jim J. Xiao, Herve Lebrec, Kathleen Köck, Wei. J. Pan, Hong Li, Samantha P. Prokop, Arunan Kaliyaperumal
Publikováno v:
Pharmacology Research & Perspectives
Hu714MuXHu is a recombinant chimeric murine-human monoclonal antibody directed against interleukin-15 (IL-15), a proinflammatory cytokine associated with memory CD8+ and natural killer (NK) T-cell activation and implicated in the pathogenesis of infl